Findings from @parkinsondotorg.bsky.social's 2026 State of the Community Survey shows what matters most to ppl affected by #Parkinson's: 52% identified non-movement symptoms - sleep disturbances, mood changes & cognitive challenges - among the most pressing concerns, alongside movement symptoms.

Today is #ChronicDiseaseAwarenessDay and Long COVID is a condition that demands our attention. BioVie is committed to advancing research for the millions navigating life with chronic conditions like #LongCOVID.

A new @jama.com study found that the number of people suffering with #longCOVID may be double current estimates. These rates translate to more than 18M Americans, and reflect the growing burden of chronic conditions following COVID-19 infection. #PASC #Neuroinflammation #BrainAwarenessMonth

Parkinson's is the second most common neurodegenerative disease after Alzheimer's disease. #Inflammation and insulin resistance are believed to be key drivers of both #ParkinsonsDisease and Alzheimer's. #AlzheimersBrainAwarenessMonth #NeuroSky

There are no approved treatments for #LongCOVID - yet millions are living with persistent brain fog, fatigue & cognitive impairment driven by neuroinflammation. BioVie's ADDRESS-LC trial is fully enrolled with data expected later this year. #BrainAwarenessMonth

1 in 5 women and 1 in 10 men will develop Alzheimer's in their lifetime. More than 12M Americans are providing unpaid care right now, and the toll on patients, families, and caregivers is profound. #AlzheimersBrainAwarenessMonth #EndALZ

Nearly 1M Americans are living with #ParkinsonsDisease, with ~ 90K new diagnoses every year. The burden on patients, caregivers, and the healthcare system is immense and will continue to grow. #OlderAmericansMonth

#ICYMI: We held a KOL event to discuss how bezisterim’s MoA - targeting #inflammation & insulin resistance in the brain - addresses the pathology & progression of #Parkinson’s disease. Watch the replay here: youtu.be/v8BGmeVvfm0

Enrollment is complete in our Phase 2 ADDRESS-LC clinical trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID, with topline data expected in late summer 2026. Learn more: investors.bioviepharma.com/news/news-de...

BioVie announced today that the last patient evaluation visit has been completed for our SUNRISE-PD Phase 2 trial evaluating bezisterim in early- stage #Parkinson’s disease. Topline data results are expected in Q3 2026. Read more: investors.bioviepharma.com/news/news-de... #Neurology #NeuroSky

During our KOL event last week, Dr. Suzanne de la Monte joined BioVie management to discuss how bezisterim’s MoA addresses the pathology + progression of neurodegenerative disease, including #Parkinson’s disease. Watch the replay: vimeo.com/1190256139/6... #Neuroinflammation #InsulinResistance

On #CINDAwareness Day we raise awareness & support those battling #MEcfs, #LongCOVID, #Parkinson’s, #Alzheimer's, & other Chronic Immunological and Neurological Diseases. BioVie is committed to advancing potential treatments for chronic neurological disorders. #NeuroSky 💙💚💜

BioVie is hosting a virtual KOL event on May 7 to discuss the P2 study of bezisterim in #Parkinson's disease ahead of upcoming topline data readout. Information & registration details here: lifescievents.com/event/psk38d0/ #Inflammation #InsulinResistance #Neurosky #Neurology

BioVie will present an abstract from the SUNRISE-PD study on its lead candidate bezisterim, in the treatment of Parkinson’s Disease at the upcoming #AANAM in Chicago. Details here: investors.bioviepharma.com/news/news-de... #ParkinsonsDisease #ScientificExchange #Neurology #NeuroSky

We stand with the millions of people living with Parkinson’s to help raise awareness, education, & hope for this progressive neurodegenerative disease that impacts movement, cognition & quality of life. #ParkinsonsAwarenessMonth #ParkinsonsResearch #HopeForPD

Dopamine is one of the most common terms associated with Parkinson’s because it helps mediate smooth, controlled muscle movements. Yet when levels in the brain are too low, motions may become slow, shaky, and halted. Why? #ParkinsonsDiseaseAwarenessMonth

During #ParkinsonsAwarenessMonth we honor people living with PD and their family, friends, nurses, & doctors who stand with them. BioVie is proud to support the Parkinson’s community and is committed to advancing innovative therapies for neurological disorders, including PD.

To all the physicians conducting research, testing new therapies, treating patients, and providing support for people with #neurological & #neurodegenerative diseases & disorders, on #NationalDoctorsDay, we say THANK YOU. #Alz #Parkinsons #longCOVID #Medsky 🩵🩺

#Parkinson’s affects ~1M people in the U.S. w/ prevalence expected to rise with aging population. Yet treatment has changed little in 50 years. Our lead drug candidate, bezisterim (NE3107), addresses the underlying neurodegeneration by targeting #inflammation that causes insulin resistance. Read ⬇️

Some of the most challenging #neurological conditions of our time share a common biology with evidence pointing to #inflammation & insulin resistance as mechanisms underlying #Alzheimer’s, #Parkinson's, & #LongCOVID. #BrainAwarenessWeek

On #LongCOVIDAwarenessDay, we recognize the millions of people still living with the debilitating effects - including #neurological symptoms such as brain fog and fatigue - long after their initial COVID-19 infection.

BioVie will present an abstract from the SUNRISE-PD study on its lead candidate bezisterim, in the treatment of #Parkinson’s at the upcoming #ADPD2026 annual meeting in Copenhagen. Details here: investors.bioviepharma.com/news/news-de... #ScientificExchange #Neurology #Neuroscience #$BIVI

Many of the most common #longCOVID symptoms are neurological - #fatigue, #brainfog, cognitive slowing, and memory decline. Research indicates that lingering #inflammation & #biological changes associated with accelerated #aging may be driving these effects in some patients.

A reminder to join us tomorrow for a live webinar with our CEO, Cuong Do, discussing bezisterim’s effects on #inflammation and insulin resistance, two key drivers of #Alzheimer’s, #Parkinson’s, and #LongCOVID. Register here: www.redchip.com/webinar/BIVI... #Neuroscience #$BIVI

Our CMO, Dr. Joseph Palumbo joined The Innovators Podcast to discuss BioVie’s mission to develop new treatments for #neurological & #neurodegenerative disorders & what it takes to bring a drug from idea to clinic. Listen here: open.spotify.com/episode/1UZX... #Parkinsons #LongCOVID #Alz

Our CEO, Cuong Do, will share updates on bezisterim for the treatment of neurological & neurodegenerative diseases during a live webinar on Wednesday, March 4. Register here: investors.bioviepharma.com/news/news-de... #Alzheimers #Parkinsons #LongCOVID #Neuroinflammation #InsulinResistance #$BIVI

Behind every person living with a neurological disease or disorder is a network of caregivers: family, friends, professionals, & advocates who provide essential support. On #NationalCaregiversDay, and every day, we recognize the critical role they play and say THANK YOU! #Alz #Parkinsons #LongCOVID

While the higher reported symptom burden in the U.S. may reflect lower stigma and greater access to neurological and mental healthcare rather than more severe disease, #brainfog and #fatigue were among the most common neurological symptoms across all countries. #LongCOVID

#Parkinson’s care has focused on dopamine for decades. BioVie (#$BIVI) is testing a different angle: targeting brain inflammation + insulin resistance. Phase 2 SUNRISE-PD enrollment complete with topline data expected Apr/May 2026. Multiple 2026 catalysts ahead. #Biotech #BIVI

BioVie announced the acceptance of two abstracts from studies on our lead candidate bezisterim, in the treatment of #Alzheimer’s & #LongCOVID at the upcoming 2026 American College of Psychiatrists (ACP) annual meeting. Read: investors.bioviepharma.com/news/news-de... #ScientificExchange #BIVI

BioVie’s current P2 ADDRESS-LC clinical trial evaluating bezisterim for the treatment of neurological symptoms associated with #LongCOVID was designed to address the unmet needs of the community and made possible with support from @solveme.bsky.social & @patientled.bsky.social.

Enrollment in BioVie’s Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for the treatment of motor & non-motor symptoms in patients with early-stage #Parkinson’s disease was made possible with the support of leading advocacy organizations.

Clinical Trials & Pharma Engagement: • Worked with @biovie.bsky.social on study design & recruitment for their Bezisterim trial for #LongCovid, an investigational drug that has shown promise in neurodegenerative conditions. /5

Our CEO, Cuong Do, spoke with @charlespiller.bsky.social about patterns of alleged misconduct at certain South Florida clinical trial sites, and the devastating implications for the Alzheimer’s community- from patients & families to researchers & drug developers seeking to make a difference.

Enrollment is complete in our Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for the treatment of motor & non-motor symptoms in patients with early-stage #Parkinson’s disease. Topline results expected in 1H 2026. Learn more: investors.bioviepharma.com/news/news-de... #Neurology #BIVI

A study published in @natimmunol.nature.com provides additional evidence that #LongCOVID is associated with chronic #inflammation & metabolic dysregulation. The findings align w/ the MoA of bezisterim, which targets upstream immune signaling involved in chronic inflammation. #BrainFog #Fatigue

Our CEO, Cuong Do, provided an update on the company’s lead candidate bezisterim currently in clinical trials for patients with #Parkinsons’s & #longCOVID. Learn about clinical & regulatory catalysts in 2026 www.youtube.com/watch?v=_RI6... #Neuroinflammation #InsulinResistance #Neuroscience

On a recent episode of Power to the Patients, our CMO Dr. Joseph Palumbo discussed why #inflammation is emerging as a critical factor in treating #neurodegenerative diseases like #Alzheimer's & #Parkinson's. Listen here: www.youtube.com/watch?v=LNXV... #Neuroscience #InsulinResistance #LongCOVID

On a recent episode of Power to the Patients podcast, our CEO Cuong Do shares how BioVie is focused on the role of #inflammation & #insulinresistance, key drivers of #Alzheimer’s, #Parkinson’s, & #LongCOVID. Listen here: bit.ly/3Kdr6nE Watch: lnkd.in/gCxPufWc #ClinicalTrials

BioVie is proud to announce that our CFO Wendy Kim was selected as a winner of the Third Annual Women CFOs of the Year Awards by the @feisv.bsky.social chapter honoring outstanding finance leaders for their achievements. bit.ly/4rBiQP3 #LifeSciences #BiotechLeadership

This month we honor those living with #Alzheimer’s and the families, clinicians, & researchers supporting them. And THANK YOU to the millions of #caregivers providing essential, heartfelt assistance to loved ones with #neurodegenerative disorders. #AlzheimersDiseaseAwareness #FamilyCaregiversMonth

We’re at #LongCOVIDIntl 2025 presenting our ongoing P2 ADDRESS-LC trial evaluating the efficacy, safety, & tolerability of bezisterim in participants with #LongCOVID enriched for #BrainFog & #fatigue. Learn about the currently enrolling trial: www.addresslongcovid.com @academicmededu.bsky.social

Earlier this month our CEO held a virtual investor webinar to discuss bezisterim for the treatment of neurological & neurodegenerative diseases. Catch the replay here: www.youtube.com/watch?v=ts_1... #Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID $BIVI

Dr. Chris Reading, SVP of our Alzheimer’s program, presented at Longevity Biotech 2025 in Boston. He discussed bezisterim’s multifaceted MoA, targeting #inflammation & #insulinresistance in the brain, 2 key drivers of #neurodegenerative disease. #Longevity #Biotech #Aging #AlzheimersDisease

A reminder to join us tomorrow for a live webinar with our CEO, Cuong Do, discussing bezisterim for the treatment of neurological & neurodegenerative diseases. Register here: investors.bioviepharma.com/news/news-de... #Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID

Our CEO, Cuong Do, will share updates on bezisterim for the treatment of neurological & neurodegenerative diseases during a live webinar on October 8. Register here: investors.bioviepharma.com/news/news-de... #Neuroinflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID #NeuroSky

On #WorldAlzheimersDay, we recognize the nearly 60M people worldwide living w/ Alzheimer’s & other forms of dementia. We're committed to advancing the science of #neuroinflammation -a root cause of #Alzheimer’s, #Parkinson’s & other diseases of #aging. #InsulinResistance #BIVI

Our CEO, Cuong Do, recently joined Kevin McCullough to share an update on the clinical trials of bezisterim for patients with #Parkinson’s disease & #LongCOVID. Listen here: podcasts.apple.com/us/podcast/t... #Neuroinflammation #InsulinResistance #Aging #ClinicalTrials #Neurology #Neurosky #BIVI

We presented the ADDRESS-LC P2 trial design of our ongoing study exploring bezisterim to treat #neurological symptoms at the #LongCOVID @keystonesymposia.bsky.social. Learn more: investors.bioviepharma.com/news/news-de... #BrainFog #Fatigue #Neuroinflammation #KSLongCOVID26

The role of neuroinflammation is no longer considered a peripheral component in the treatment of #Parkinson’s disease. It is central… and offers a new array of therapeutic promise. @parkinsondotorg.bsky.social @gohealio.bsky.social #Neuroinflammation #InsulinResistance #Neurology #Neurosky